Pulmonary Embolism News and Research

RSS
A pulmonary embolism is a sudden blockage in a lung artery. The cause is usually a blood clot in the leg called a deep vein thrombosis that breaks loose and travels through the bloodstream to the lung.
Enrollment commences for Daiichi Sankyo's ENSURE-AF multinational phase 3 study in NVAF patients

Enrollment commences for Daiichi Sankyo's ENSURE-AF multinational phase 3 study in NVAF patients

SEATTLE II study confirms safety and efficacy of thrombolytic therapy for acute PE

SEATTLE II study confirms safety and efficacy of thrombolytic therapy for acute PE

New approach can improve patient outcomes, reduce complications in complex spine surgeries

New approach can improve patient outcomes, reduce complications in complex spine surgeries

ISTH declares Oct.13 as World Thrombosis Day

ISTH declares Oct.13 as World Thrombosis Day

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Study finds higher readmission rates for same-day total joint replacement surgery

Study finds higher readmission rates for same-day total joint replacement surgery

Nintedanib plus docetaxel shows second-line efficacy in recurrent NSCLC

Nintedanib plus docetaxel shows second-line efficacy in recurrent NSCLC

Women's blood clot risk remains elevated for at least 12 weeks after delivering a baby, says study

Women's blood clot risk remains elevated for at least 12 weeks after delivering a baby, says study

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Viewpoints: Mass. abortion debate comes down to 35 feet; Tampa mayor leads charge to get young people signed up for health care

Viewpoints: Mass. abortion debate comes down to 35 feet; Tampa mayor leads charge to get young people signed up for health care

Argon gets FDA clearance to market OptionELITE IVC filter over-the-wire delivery technique

Argon gets FDA clearance to market OptionELITE IVC filter over-the-wire delivery technique

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

Daiichi Sankyo submits Marketing Authorization Application for edoxaban to EMA

Daiichi Sankyo submits Marketing Authorization Application for edoxaban to EMA

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

Daiichi Sankyo submits LIXIANA supplemental NDA for review in Japan

Daiichi Sankyo submits LIXIANA supplemental NDA for review in Japan

Late-breaking abstracts on treatment of blood cancers and bleeding disorders presented at ASH meeting

Late-breaking abstracts on treatment of blood cancers and bleeding disorders presented at ASH meeting

Findings may help clinicians determine which hospitalized children at greatest risk of VTE

Findings may help clinicians determine which hospitalized children at greatest risk of VTE

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Daiichi Sankyo presents subgroup analysis of Hokusai-VTE study at ASH annual meeting

Daiichi Sankyo presents subgroup analysis of Hokusai-VTE study at ASH annual meeting

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.